Rebalancing the Immune System: The MultiStem® Cellular Platform for Treating Disease and Injury

Preclinical research using MultiStem cells has shown Multipotent Adult Progenitor Cells, or MAPC®, may be beneficial in the treatment of a variety of critical care and difficult to treat inflammatory diseases. On Monday, August 29, 2022, Dr. Robert W. Mays, Executive Vice President and Head of Regenerative Medicine & Neuroscience Programs, and Dr. Sarah Busch, Vice President, Regenerative Medicine & Head of Nonclinical Development, will be hosting a webinar to provide a comprehensive update on the Company’s preclinical programs.
Be the first to comment